Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Effect of Opicapone at Steady State on Warfarin Pharmacokinetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02305030
Recruitment Status : Completed
First Posted : December 2, 2014
Last Update Posted : December 2, 2014
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
Single-centre, open-label, fixed-sequence design consisting of 2 periods separated by a washout period of at least 14 days.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: BIA 9-1067 Drug: Warfarin Phase 1

Detailed Description:
Single-centre, open-label, fixed-sequence design consisting of 2 periods separated by a washout period of at least 14 days. In Period 1, a single dose of 25 mg warfarin was administered alone. In Period 2, subjects received 475 mg OPC, on Day 1 and D2 followed by 50 mg OPC once daily for 5 days (D3 to D7). On D8, 50 mg OPC was administered with a single dose of 25 mg warfarin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers
Study Start Date : March 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: BIA 9-1067 / Warfarin
BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
Drug: BIA 9-1067
Other Name: OPC, Opicapone

Drug: Warfarin
Other Name: Uniwarfin

Primary Outcome Measures :
  1. R- and S-warfarin plasma concentration [ Time Frame: pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 and 144 h post-warfarin ]

Secondary Outcome Measures :
  1. Opicapone plasma concentration [ Time Frame: D1 pre-dose, and on D8 at the following time points: pre-dose, 0.5, 2, 4, 6, and 8 h post-opicapone dose ]
  2. BIA 9-1103 (sulphate metabolite) plasma concentration [ Time Frame: D1 pre-dose and from D5 to D7 pre-dose, and on D8 at the following time points: pre-dose, 0.5, 2, 4, 6, 8, 24, 48, 72 and 144 h post-opicapone dose. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • A signed and dated informed consent form before any study-specific screening procedure was performed,
  • Male or female subjects aged 18 to 45 years, inclusive,
  • Body mass index (BMI) between 18 and 30 kg/m2,
  • Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG),
  • Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies and anti-human immunodeficiency virus (HIV) antibodies at screening,
  • Clinical laboratory test results clinically acceptable at screening and at admission to each inpatient period,
  • Negative screen for alcohol and drugs of abuse at screening and at admission to each inpatient period,
  • Non-smokers or ex-smokers for at least 3 months,
  • Able to participate, and willing to give written informed consent and comply with the study restrictions,
  • Able to swallow a high number of capsules within a short time frame,

If female:

  • Was not of childbearing potential by reason of surgery or, if of childbearing potential, used an effective non-hormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap [diaphragm or cervical or vault caps] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject) for the entire duration of the study,
  • Negative serum pregnancy test at screening and a negative urine pregnancy test at admission to each inpatient period.

Exclusion Criteria:

  • Any clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or had a clinically relevant surgical history,
  • Any personal or family history of haemostatic disorder,
  • Any personal or family history of bleeding complications after surgery or tooth extraction, nose or gingival bleeding, or haemorrhagic diathesis,
  • Any clinically relevant findings in the laboratory tests, particularly any abnormality in the coagulation tests or the liver function tests,
  • History of relevant atopy or drug hypersensitivity,
  • History of alcoholism and/or drug abuse,
  • Current consumption of more than 14 units of alcohol per week [1 unit of alcohol = 280 mL beer (3-4°) = 100 mL wine (10-12°) = 30 mL spirits (40°)],
  • Any significant infection or known inflammatory process on screening or admission to each treatment period; any acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period,
  • Use of medicines within 2 weeks of admission to first period that could affect the subject's safety or other study assessments, in the investigator's opinion, or intake of any of the prohibited medications (i.e., CYP2C9 inhibitor taken within 1 week prior to start of administration of study drug, and CYP2C9 inducer taken within 4 weeks prior to dosing),
  • Previous use of opicapone,
  • Use of any investigational drug or participation in any clinical trial within 3 months prior to screening; participation in more than 2 clinical trials within the 12 months prior to screening,
  • Blood donation or receipt of any blood transfusion or any blood products within the 3 months prior to screening,
  • Vegetarian, vegan or had medical dietary restrictions,
  • Not able to communicate reliably with the investigator,
  • Unlikely to co-operate with the requirements of the study,
  • Unwilling or unable to give written informed consent,
  • CYP2C9 poor metaboliser, as assessed by genotyping,

If female:

  • Pregnant or breast-feeding.

Layout table for additonal information
Responsible Party: Bial - Portela C S.A. Identifier: NCT02305030    
Other Study ID Numbers: BIA-91067-127
First Posted: December 2, 2014    Key Record Dates
Last Update Posted: December 2, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Catechol O-Methyltransferase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiparkinson Agents
Anti-Dyskinesia Agents